Literature DB >> 1380833

Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.

G Capranico1, S Tinelli, C A Austin, M L Fisher, F Zunino.   

Abstract

The expression of DNA topoisomerase II alpha and beta genes was studied in murine normal tissues. Northern blot analysis using probes specific for the two genes showed that the patterns of expression were different among 22 tissues of adult mice. Expression levels of topoisomerase II alpha gene were high in proliferating tissues, such as bone marrow and spleen, and undetectable or low in 17 other tissues. In contrast, high or intermediate expression of topoisomerase II beta gene was found in a variety of tissues (15) of adult mice, including those with no proliferating cells. Topoisomerase II gene expression was also studied during murine development. In whole embryos both genes were expressed at higher levels in early than late stages of embryogenesis. Heart, brain and liver of embryos two days before delivery, and these same tissues plus lung and thymus of newborn (1-day-old) mice expressed appreciable levels of the two genes. Interestingly, a post-natal induction of the beta gene expression was observed in the brain but not in the liver; conversely, the expression of the alpha gene was increased 1 day after birth in the liver but not in the brain. However, gene expression of a proliferation-associated enzyme, thymidylate synthase, was similar in these tissues between embryos and newborns. Thus, the two genes were differentially regulated in the post-natal period, and a tissue-specific role may be suggested for the two isoenzymes in the development of differentiated tissues such as the brain and liver. Based on the differential patterns of expression of the two isoforms, this analysis indicates that topoisomerase II alpha may be a specific marker of cell proliferation, whereas topoisomerase II beta may be implicated in functions of DNA metabolism other than replication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380833     DOI: 10.1016/0167-4781(92)90050-a

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  68 in total

1.  Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Authors:  Adrian G Grozav; Belinda B Willard; Toshiyuki Kozuki; Kenichi Chikamori; Marius A Micluta; Andrei-Jose Petrescu; Michael Kinter; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

2.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

3.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 4.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

Review 5.  Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Authors:  Jean Domercant; Nichole Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2016

6.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

Authors:  Anna M Azarova; Yi Lisa Lyu; Chao-Po Lin; Yuan-Chin Tsai; Johnson Yiu-Nam Lau; James C Wang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

7.  Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

Authors:  Lisa M Oppegard; Andrei V Ougolkov; Doris N Luchini; Renee A Schoon; John R Goodell; Harneet Kaur; Daniel D Billadeau; David M Ferguson; Hiroshi Hiasa
Journal:  Eur J Pharmacol       Date:  2008-12-03       Impact factor: 4.432

8.  The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

Authors:  Timothy J Wendorff; Bryan H Schmidt; Pauline Heslop; Caroline A Austin; James M Berger
Journal:  J Mol Biol       Date:  2012-07-25       Impact factor: 5.469

Review 9.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

Review 10.  Topoisomerase II: a fitted mechanism for the chromatin landscape.

Authors:  Joaquim Roca
Journal:  Nucleic Acids Res       Date:  2008-12-05       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.